SCHEMBL1086258

SCHEMBL1086258

O=C(O)N1CCC2(CC1)CN(Cc1ccc(C(F)(F)F)cc1)C(=O)O2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.43
SSTR5 P35346 4/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
HDAC1 Q13547 1/20 0.40
EPHX1 P07099 1/20 0.40
EPHX2 P34913 1/20 0.40
TACR2 P21452 1/20 0.40
TACR1 P25103 1/20 0.40
GRM2 Q14416 1/20 0.40
FAAH O00519 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
USP2 O75604 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486406 0.90 MGLL (0.42) MGLLSSTR5SIRT2SIRT1HDAC1
SCHEMBL4486408 0.90 POLB (0.40) MGLLSSTR5SIRT2SIRT1POLB
SCHEMBL18445998 0.87 TACR2 (0.48) MGLLPOLBTACR2TACR1GRM2
SCHEMBL1086645 0.87 POLB (0.41) MGLLSSTR5SIRT2SIRT1POLB
SCHEMBL1086750 0.86 USP2 (0.56) EPHX1EPHX2TACR1USP2
SCHEMBL1086423 0.86 TACR2 (0.39) MGLLSSTR5TACR2TACR1GRM2
SCHEMBL1085855 0.86 RIPK1 (0.49) MGLLPOLBTACR2TACR1GRM2
SCHEMBL12184852 0.85 SSTR5 (0.55) SSTR5POLBGAA
SCHEMBL1086209 0.85 GRM2 (0.42) SSTR5TACR2TACR1GRM2FAAH
SCHEMBL1086607 0.85 TSHR (0.47) GAATACR2TACR1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC MGLL 3543/4885SSTR5 413/4885SIRT2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.